Novo Nordisk A/S vs Charles Schwab Corporation Common Stock — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Charles Schwab Corporation Common Stock trades at $100.17 (market cap $178.33B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | SCHW | |
|---|---|---|
Market Cap | $220.53B | $178.33B |
Sector | Health | Financials |
52-Week High | $71.70 | $107.21 |
52-Week Low | $35.29 | $85.35 |
Enterprise Value | $239.49B | — |
Dividend Yield | 3.63% | 1.25% |
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →